Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy

BACKGROUND: We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer. METHODS: The effect of increasing sorafenib doses on proliferation, apoptosis, migration, and activation of signal cascades was analyz...

Full description

Saved in:
Bibliographic Details
Main Authors: Wehler, Thomas C., Hamdi, Swaantje, Maderer, Annett, Graf, Claudine, Gockel, Ines, Schmidtmann, Irene, Hainz, Michael, Berger, Martin R., Theobald, Matthias, Galle, Peter R., Moehler, Markus, Schimanski, Carl C.
Format: Artigo
Language:Inglês
Published: Springer-Verlag 2012
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587684/
https://ncbi.nlm.nih.gov/pubmed/22983756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00384-012-1551-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items